Genetic Variants in One-Carbon Metabolism Pathway Predict Survival Outcomes of Early-Stage Non-Small Cell Lung Cancer

Oncology ◽  
2020 ◽  
Vol 98 (12) ◽  
pp. 897-904
Author(s):  
Sook Kyung Do ◽  
Sun Ha Choi ◽  
Shin Yup Lee ◽  
Jin Eun Choi ◽  
Hyo-Gyoung Kang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Carbon Metabolism ◽  
Genetic Variants ◽  
Early Stage ◽  
Small Cell ◽  
Survival Outcomes ◽  
Small Cell Lung ◽  
Metabolism Pathway ◽  
One Carbon Metabolism ◽  
The One

<b><i>Background:</i></b> This study was conducted to investigate the association between genetic variants in one-carbon metabolism and survival outcomes of surgically resected non-small cell lung cancer (NSCLC). <b><i>Methods:</i></b> We genotyped 41 potentially functional variants of 19 key genes in the one-carbon metabolism pathway among 750 NSCLC patients who underwent curative surgery. The association between genetic variants and overall survival (OS)/disease-free survival (DFS) were analyzed. <b><i>Results:</i></b> Among the 41 single-nucleotide polymorphisms (SNPs) analyzed, 4 SNPs (<i>MTHFD1L</i> rs6919680T&#x3e;G and rs3849794T&#x3e;C, <i>MTR</i> rs2853523C&#x3e;A, and <i>MTHFR</i> rs4846049G&#x3e;T) were significantly associated with survival outcomes. <i>MTHFD1L</i> rs6919680T&#x3e;G and <i>MTR</i> rs2853523C&#x3e;A were significantly associated with better OS (adjusted hazard ratio [aHR] = 0.73, 95% confidence interval [CI] = 0.54–0.99, <i>p</i> = 0.04) and worse OS (aHR = 2.14, 95% CI = 1.13–4.07, <i>p</i> = 0.02), respectively. <i>MTHFD1L</i> rs3849794T&#x3e;C and <i>MTHFR</i> rs4846049G&#x3e;T were significantly associated with worse DFS (aHR = 1.41, 95% CI = 1.08–1.83, <i>p</i> = 0.01; and aHR = 1.97, 95% CI = 1.10–3.53, <i>p</i> = 0.02, respectively). When the patients were divided according to histology, the associations were significant only in squamous cell carcinoma (SCC), but not in adenocarcinoma (AC). In SCC, <i>MTHFD1L</i> rs6919680T&#x3e;G and <i>MTR</i> rs2853523C&#x3e;A were significantly associated with better OS (aHR = 0.64, 95% CI = 0.41–1.00, <i>p</i> = 0.05) and worse OS (aHR = 2.77, 95% CI = 1.11–6.91, <i>p</i> = 0.03), respectively, and <i>MTHFD1L</i> rs3849794T&#x3e;C and <i>MTHFR</i> rs4846049G&#x3e;T were significantly associated with worse DFS (aHR = 1.73, 95% CI = 1.17–2.56, <i>p</i> = 0.01; and aHR = 2.78, 95% CI = 1.12–6.88, <i>p</i> = 0.03, respectively). <b><i>Conclusions:</i></b> Our results suggest that the genetic variants in the one-carbon metabolism pathway could be used as biomarkers for predicting the clinical outcomes of patients with early-stage NSCLC.

scholarly journals Polymorphisms in mitotic checkpoint-related genes can influence survival outcomes of early-stage non-small cell lung cancer

Oncotarget ◽  
2017 ◽  
Vol 8 (37) ◽  
pp. 61777-61785 ◽  
Author(s):  
Hyo Gyoung Kang ◽  
Seung Soo Yoo ◽  
Jin Eun Choi ◽  
Mi Jeong Hong ◽  
Sook Kyung Do ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Mitotic Checkpoint ◽  
Small Cell ◽  
Survival Outcomes ◽  
Small Cell Lung

scholarly journals Stereotactic body radiation therapy versus surgery for patients with early-stage non–small cell lung cancer( ≤ 5cm): A systematic review and meta-analysis

2021 ◽  
Author(s):  
Yueling Zhou ◽  
Ping Wen ◽  
Yue Yu ◽  
Zhenyi Yang ◽  
Yixuan Luo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Radiation Therapy ◽  
Stereotactic Body Radiation Therapy ◽  
Early Stage ◽  
Meta Analysis ◽  
Small Cell ◽  
Survival Outcomes ◽  
Small Cell Lung ◽  
Early Stage Nsclc

Abstract Background: Stereotactic body radiation therapy (SBRT) is considered as the preferred treatment method for inoperable early-stage non-small cell lung cancer (NSCLC). However, there is still a debate on the efficacy of SBRT and surgery. This meta-analysis aimed to compare survival outcomes of SBRT and surgery for early-stage NSCLC (≤5cm).Methods: A systematic review and meta-analysis were performed to compare survival outcomes of surgery and SBRT. And the pooled analysis was conducted with STATA 14.0 software. Results: Thirty-nine comparative studies were included for systematic review and twenty-eight of which for quantitative analysis. Compared with SBRT, overall survival (OS) was superior after surgical resection, included lobectomy, sublobar resection, video-assisted thoracoscopic surgery, and thoracotomy, for patients with early-stage NSCLC (≤5cm). And the results of subgroup analysis remained the support of surgery except for the OS of operable matched cohorts and the one matched cohort of age ≥75. However, the HR of OS showed a reduction from patients with unspecific age, ≥65 to ≥75 years old and histopathologically confirmed NSCLC to clinical NSCLC. Although cancer-specific survival and local control was superior after surgery, the recurrence rate of tumors, locoregional control, distant control, and regional control of matched patients demonstrated no significantly different outcomes between SBRT and surgery for early-stage NSCLC.Conclusions: Results show that surgery has superior OS, CSS and local control compared to SBRT for early-stage NSCLC. There is still necessary to explore the survival difference between SBRT and surgery for patients with different characteristics by large-sample, long-term follow-up randomized clinical studies.

scholarly journals Functional intronic variant of SLC 5A10 affects DRG 2 expression and survival outcomes of early‐stage non‐small‐cell lung cancer

2018 ◽  
Vol 109 (12) ◽  
pp. 3902-3909 ◽  
Author(s):  
Mi Jeong Hong ◽  
Seung Soo Yoo ◽  
Jin Eun Choi ◽  
Hyo‐Gyoung Kang ◽  
Sook Kyung Do ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Small Cell ◽  
Survival Outcomes ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document